
|Articles|March 1, 2020
- Pharmaceutical Executive-03-01-2020
- Volume 40
- Issue 3
Pharmaceutical Executive, March 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
The Multichannel Reach: Balancing the Local and Global Voicealmost 6 years ago
Market Access: From Being to Becomingalmost 6 years ago
Consider Data Before It’s a Problemalmost 6 years ago
Multichannel Marketing: Integrating Omnichannelalmost 6 years ago
Feds Target Biosimilar Anticompetitive Practicesalmost 6 years ago
Blood Feud Divides Europe Over Plasma Shortfallsalmost 6 years ago
Social Media’s Influence in Messaging Mixalmost 6 years ago
Habib Bennaceur: Following the Sciencealmost 6 years ago
A Bad Deal with Data?almost 6 years ago
Country Report: United Arab EmiratesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
President Trump Announces Nine More TrumpRx Participants
5




